PD1+ TILs (NUMARZU-001) product infusion for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 11 Jul 2022: Trial registered, NCT05451784
  2. 20 Jul 2022: Trial started, NCT05451784

The trials

NCT05451784: Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS

State
Under way
Phase
Phase 1 and Phase 2
People
20 planned
Started
20 Jul 2022
Primary completion
30 Sep 2028
Arms
PD1+ TILs (NUMARZU-001) product infusion
Results
None posted
  1. 11 Jul 2022: Trial registered
  2. 20 Jul 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.